» Articles » PMID: 36972008

Optimization of β-Lactam Dosing Regimens in Neonatal Infections: Continuous and Extended Administration Versus Intermittent Administration

Overview
Specialty Pharmacology
Date 2023 Mar 27
PMID 36972008
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objective: In neonates, β-Lactam antibiotics are almost exclusively administered by intermittent infusion. However, continuous or prolonged infusion may be more beneficial because of the time-dependent antibacterial activity. In this pharmacokinetic/pharmacodynamic simulation study, we aimed to compare treatment with continuous, extended and intermittent infusion of β-lactam antibiotics for neonates with infectious diseases.

Methods: We selected population pharmacokinetic models of penicillin G, amoxicillin, flucloxacillin, cefotaxime, ceftazidime and meropenem, and performed a Monte Carlo simulation with 30,000 neonates. Four different dosing regimens were simulated: intermittent infusion in 30 min, prolonged infusion in 4 h, continuous infusion, and continuous infusion with a loading dose. The primary endpoint was 90% probability of target attainment (PTA) for 100% ƒT>MIC during the first 48 h of treatment.

Results: For all antibiotics except cefotaxime, continuous infusion with a loading dose resulted in a higher PTA compared with other dosing regimens. Sufficient exposure (PTA >90%) using continuous infusion with a loading dose was reached for amoxicillin (90.3%), penicillin G (PTA 98.4%), flucloxacillin (PTA 94.3%), cefotaxime (PTA 100%), and ceftazidime (PTA 100%). Independent of dosing regimen, higher meropenem (PTA for continuous infusion with a loading dose of 85.5%) doses might be needed to treat severe infections in neonates. Ceftazidime and cefotaxime dose might be unnecessarily high, as even with dose reductions, a PTA > 90% was retained.

Conclusions: Continuous infusion after a loading dose leads to a higher PTA compared with continuous, intermittent or prolonged infusion, and therefore has the potential to improve treatment with β-lactam antibiotics in neonates.

Citing Articles

Population pharmacokinetics and dose optimization of ceftazidime in critically ill children.

Li M, Gao L, Wang Z, Zeng L, Chen C, Wang J Front Pharmacol. 2024; 15:1470350.

PMID: 39664522 PMC: 11631598. DOI: 10.3389/fphar.2024.1470350.


Continuous versus intermittent infusion of beta-lactam antibiotics: where do we stand today? A narrative review.

Alawyia B, Fathima S, Spernovasilis N, Alon-Ellenbogen D Germs. 2024; 14(2):162-178.

PMID: 39493742 PMC: 11527492. DOI: 10.18683/germs.2024.1428.


Effect of β-lactam antibiotics on the gut microbiota of term neonates.

Gu H, Tao E, Fan Y, Long G, Jia X, Yuan T Ann Clin Microbiol Antimicrob. 2024; 23(1):69.

PMID: 39113137 PMC: 11308410. DOI: 10.1186/s12941-024-00730-2.


[Clinical practice guidelines for meropenem therapy in neonatal sepsis (2024)].

Zhongguo Dang Dai Er Ke Za Zhi. 2024; 26(2):107-117.

PMID: 38436306 PMC: 10921874. DOI: 10.7499/j.issn.1008-8830.2309059.

References
1.
Martinez M, Papich M, Drusano G . Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target. Antimicrob Agents Chemother. 2012; 56(6):2795-805. PMC: 3370717. DOI: 10.1128/AAC.05360-11. View

2.
Drusano G . Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol. 2004; 2(4):289-300. DOI: 10.1038/nrmicro862. View

3.
Guilhaumou R, Benaboud S, Bennis Y, Dahyot-Fizelier C, Dailly E, Gandia P . Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of.... Crit Care. 2019; 23(1):104. PMC: 6441232. DOI: 10.1186/s13054-019-2378-9. View

4.
Vardakas K, Voulgaris G, Maliaros A, Samonis G, Falagas M . Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials. Lancet Infect Dis. 2017; 18(1):108-120. DOI: 10.1016/S1473-3099(17)30615-1. View

5.
Roberts J, Abdul-Aziz M, Davis J, Dulhunty J, Cotta M, Myburgh J . Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials. Am J Respir Crit Care Med. 2016; 194(6):681-91. DOI: 10.1164/rccm.201601-0024OC. View